Nexalin Technology, Inc.

NXL Nasdaq CIK: 0001527352

Company Information

Industry Electromedical & Electrotherapeutic Apparatus
SIC Code 3845
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 1776 YORKTOWN, HOUSTON, TX, 77056
Mailing Address 1776 YORKTOWN, HOUSTON, TX, 77056
Phone (832) 260-0222
Fiscal Year End 1231
EIN 275566468

Financial Overview

FY2024 FY

$169K
Revenue

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events January 23, 2026 View on SEC
4 Insider stock transaction report December 23, 2025 View on SEC
4 Insider stock transaction report December 23, 2025 View on SEC
4 Insider stock transaction report December 23, 2025 View on SEC
4 Insider stock transaction report December 23, 2025 View on SEC
4 Insider stock transaction report December 23, 2025 View on SEC
4 Insider stock transaction report December 23, 2025 View on SEC
8-K Current report of material events December 5, 2025 View on SEC
10-Q Quarterly financial report November 14, 2025 View on SEC
424B5 Prospectus supplement October 15, 2025 View on SEC

Material Events

8-K Financial Distress January 23, 2026
High Impact
  • The Nasdaq deficiency notice does not immediately affect the listing or trading of the Company’s common stock.
  • The Company has an initial 180-calendar-day period, until July 20, 2026, to regain compliance.
View Analysis

Related Companies

Companies in the same industry (SIC: 3845)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.